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rug-eluting stents (DES) considerably reduce rates of
estenosis and related target vessel revascularization com-
ared with bare-metal stents (BMS). Although patient
urvival is not significantly increased by DES, concern has
een growing that delayed endothelialization, incomplete
eointimal healing, inflammatory events, or hypersensitivity
eactions after DES implantation may lead to serious adverse
vents such as vasospasms and stent thrombosis, and conse-
uently may trigger myocardial infarction and death (1).
See page 2321
Drugs released from DES exert distinct biological effects,
uch as (in)activation of signal transduction pathways and
nhibition of cell proliferation. Although primarily aimed at
reventing vascular smooth muscle cell (VSMC) pro-
iferation and migration, these drugs also impair re-
ndothelialization and induce tissue factor expression, re-
ulting in a prothrombogenic environment (2). DES
mplanted in noninjured common swine coronary arteries
rovoke an extensive granulomatous, eosinophil-rich in-
ammatory response with circumferential vessel involve-
ent in all stented sections. Inflammation was also observed
n BMS control subjects, but at a much lower prevalence
nd with less intensity (3). DES, but not BMS, are
ssociated with acetylcholine- or exercise-induced paradox-
cal coronary vasoconstriction of the adjacent vessel seg-
ents (4,5). These observations suggest a drug-induced
ndothelial and/or vascular dysfunction as the underlying
echanism. Whether this effect is directly and specifically
rug-induced or whether this is the result of a prolonged
nflammatory response with concomitant delayed recovery
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onn, Germany.f the endothelium and other vascular tissues remains
nclear.
In this issue of the Journal, Shiroto et al. (6) showed that
aclitaxel increases Rho-kinase (ROCK) expression and activ-
ty in cultured human coronary VSMCs. After paclitaxel- or
irolimus-eluting stent implantation in porcine coronary arter-
es, serotonin-mediated vasoconstriction at the stent edges was
ore enhanced in DES than in BMS. This hyperconstriction
ould be diminished by intracoronary pre-treatment with
ydroxyfasudil, a selective ROCK inhibitor. Bradykinin-
ediated vasodilation was not altered. Histological analyses
howed a suppression of neointimal formation and re-
ndothelialization in DES sites compared with BMS sites.
icrothrombus formation and inflammatory response at
ES sites were enhanced. Immunohistological analyses also
etected a higher expression of ROCK at the DES sites.
This nice work by Shiroto et al. (6) suggests that the
OCK pathway plays an important pathogenetic role in
oronary hyperconstriction after DES implantation. The
resent study deals with a very important issue, provoking
dditional questions:
. Although it is well accepted that stent thrombosis is
succeeded by serious clinical end points, it is unsettled
whether vascular hyperconstriction is frequently the
cause of adverse events. Coronary vasospasm has been
postulated to play an important role, especially in the
Japanese population (7), in variant angina, but also in
unstable angina, myocardial infarction, and sudden car-
diac death (8). Coronary artery spasms caused by a local
hyper-reactivity of the arterial wall may contribute to the
development of occlusive coronary thrombosis by fissur-
ing a plaque or the vessel wall and by leading to blood
stasis (9). However, the link between adverse clinical
events and persistent abnormal vasomotion after DES
implantation has yet to be established.
. It would be interesting to know whether DES-induced
hyperconstriction predominately occurs in individuals
who are a priori predisposed to abnormal vasospasms.
This could shed some light on the underlying mecha-
nisms. Is Rho-kinase generally instrumental for the
development of clinically relevant vasospasms?
. Obviously, it remains to be determined whether investi-
gation and treatment of healthy porcine vessels is trans-
ferable to the clinical scenario in humans, where we
commonly deal with vascular structures severely altered
by atherogenesis. So far, patients with atherosclerotic
lesions may display paradoxical exercise- and acetylcholine-
induced vasoconstriction of vessel segments adjacent
to sirolimus-eluting stents, although the endothelium-
independent dilatory response to nitroglycerin was
maintained (4,5,10). The underlying mechanisms
(possibly Rho?) were not clarified.
. Is the coronary hyperconstriction, especially found at
DES sites, a direct and specific drug effect of paclitaxel or
sirolimus, or is it rather a result of prolonged and
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messenger ribonucleic acids and ROCK-proteins are
up-regulated through protein kinase C- and nuclear
factor kappa B-dependent pathways by proinflammatory
factors such as angiotensin II and interleukin-1 beta. The
ROCK pathway modulates the phosphorylation level of
myosin light chain through inhibition of myosin phos-
phatase and contributes to the agonist-induced calcium
sensitization in smooth muscle contraction (8). Activa-
tion of the ROCK pathway down-regulates endothelial
nitric oxide synthase and thereby reduces bioavailability
of nitric oxide, promoting endothelial dysfunction (11).
Thus, ROCK activation might be a central mechanism
for both endothelial dysfunction and VSMC hypercon-
striction, causing general vascular dysfunction.
Because long-term inhibition of ROCK with fasudil
suppresses the in-stent neointimal formation by multiple
mechanisms, including inhibition of vascular inflamma-
tion, enhanced apoptosis, and reduced collagen deposi-
tion (12), increased ROCK activity at the stent site could
also be an epiphenomenon of the inflammatory process
of the vessel wall, which is aggravated by paclitaxel or
sirolimus at the DES sites. At least, a recent study
observed more extensive inflammatory reactions at DES
(especially in sirolimus-eluting stents) than at BMS sites
in a porcine model (3). After all, the expression of
ROCK itself is accelerated by inflammatory stimuli.
These inflammatory processes may partly explain the
hyperconstricting responses after DES implantation.
. What is the impact of anti-inflammatory treatment on
the observed events? Although a recent study observed
an antirestenotic efficacy of oral prednisone treatment
after percutaneous coronary intervention with conven-
tional BMS (13), the impact of steroid administration
after DES implantation especially with respect to hyper-
constriction is unknown, but may help to elucidate the
role of the DES-induced inflammatory response of the
vessel wall.
. By the same token, is the inflammatory cascade directly
initiated by the eluting drugs? What is the role of the
polymer? The exemplary data in cultured VSMCs sug-
gest direct effects of paclitaxel (sirolimus?). However,
those cells are not comparable with the quiescent and
contracting cells residing in the media of an adult vessel.
In addition, in vivo hyperconstriction may not be purely
mediated via VSMC action, but may also be influenced
by other adjacent cells (endothelial or inflammatory cells)
as well as by extracellular factors (matrix, cytokines,
growth factors, and so on). If we are looking at a
cell-specific mechanism taking place only in smooth
muscle and not in endothelial cells, the underlying
mechanisms need attention imperatively because this
could guide us to the desperately needed differential
vascular therapy required to selectively foster the endo-
thelial and afflict the muscle cells. Thus, further research
would need to definitely exclude the possibility that thepolymer rather than the drugs is responsible for the
observed hyperconstriction.
. Is the pathway specific for serotonin? In coronary an-
giography, serotonin provokes more focal coronary vaso-
spasm, whereas acetylcholine induces more diffuse and
distal vasospasm (8,14). Obviously, coronary artery spasms
frequently occur at the atherosclerotic lesions of the coro-
nary artery. Revealing a close topological correlation be-
tween the serotonin-induced spastic site and the atheroscle-
rotic lesion, serotonin seems to better mimic spontaneous
coronary spasms than acetylcholine in vivo (8,15). It would
be nice to know whether vasoconstrictors, such as nor-
epinephrine, angiotensin II, or endothelin, also provoke
hyperconstriction after DES implantation. If so, effective
treatment options to test this hypothesis would be
available.
. Would statin treatment ameliorate the DES-associated
vasoconstriction? By inhibiting the 3-hydroxy-3-
methylglutaryl coenzyme A reductase, statins reduce cho-
lesterol synthesis, thus preventing the formation of
geranylgeranyl pyrophosphate required for membrane
translocation and activation of Rho-A, the main up-
stream activator of ROCK (16). Because ROCK inhibi-
tion results in the stabilization of endothelial nitric oxide
synthase–messenger ribonucleic acid and an increased
bioavailability of nitric oxide (17,18), this, as one of the
so-called pleiotropic effects of statins, is thought to be
responsible for the observed improvement in flow-
mediated vasodilation by statin administration. Do we
need a drug such as fasudil, with an uncertain safety
profile, if we could instead select the widely used statins?
The findings of Shiroto et al. (6) add valuable informa-
ion to the DES issue and underline the importance of
etter understanding the mechanisms responsible for the
ascular performance, and supposedly, the clinical outcome
fter DES implantation. As almost always, we implemented
ith DES a treatment option in humans that we have (at
est) not fully mechanistically anticipated. Although no one
ill dispute the clinical success of this venture, much work
eeds to be accomplished not only to better understand the
olecular and cellular events critical for vascular pathology
ith or without stents, but also to develop therapeutic
easures that will improve patient outcome. Certainly, the
OCK pathway is one attractive candidate.
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